GENE ONLINE|News &
Opinion
Blog

Gene Therapy
Go Prime Gene Therapy
How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?
2022-07-08
Special Gene and Cell Therapy
Gene & Cell Therapy’s Big Leaps in the Past 5 Years
2022-07-08
Trials & Approvals Haemophilia
BioMarin Wins First Gene Therapy Recommendation For Hemophilia A in Europe
2022-06-27
Trials & Approvals RNAi Therapeutics
FDA Approves Alnylam’s Rare Disease RNAi Therapeutic
2022-06-15
Funding Gene Therapy
Astellas Ups Production of Gene Therapies With New Carolina Plant
2022-06-09
Trials & Approvals Spinal Muscular Atrophy
First Oral SMA Drug by Roche Now Available to Newborns
2022-06-01
Funding Gene Therapy
Kriya Bags $270 Million Series C to Support Integrated Gene Therapies
2022-05-18
R&D CRISPR
Innovative Supramolecular Carriers Help CRISPR-Cas9 Enter Cells Effectively
2022-05-12
Funding CAR T-cell Therapy
Boston’s Kelonia Therapeutics Bags $50M to Accelerate Genetic Medicines
2022-04-29
Deals Astellas Pharma
Astellas Ditches Gene Therapies, with Losses Exceeding $390 Million
2022-04-25
Licensing Gene Therapy
Novartis Bets $1.5 Billion on Voyager’s AAVs
2022-03-09
Asia-Pacific Gene Therapy
Takeda Taps Code Biotherapeutics to Develop Non-Viral Gene Therapies in $2 Billion Biobucks Deal
2022-02-23
Regulatory Gene Therapy
Homology Medicines Joins Biomarin in Gene Therapy Clinical Hold
2022-02-22
Editors' Picks Gene Therapy
BIO CEO: Overcoming the Obstacles in Developing Gene Therapies
2022-02-21
Technology Gene Therapy
What If Our Body’s Power Station Goes Wrong? Gene Therapy May Help
2022-02-15
1 2 3 4 5 … 9
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top